Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial-Reference-Cited by-同舟云学术

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

Published:2015-02 Issue:2 Volume:26 Page:415-421
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Menzies A.M.,Ashworth M.T.,Swann S.,Kefford R.F.,Flaherty K.,Weber J.,Infante J.R.,Kim K.B.,Gonzalez R.,Hamid O.,Schuchter L.,Cebon J.,Sosman J.A.,Little S.,Sun P.,Aktan G.,Ouellet D.,Jin F.,Long G.V.,Daud A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/2/415/24065201/mdu529.pdf

Reference20 articles.

1. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

2. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet,2012

3. Improved survival with MEK inhibition in BRAF-mutated melanoma;Flaherty;N Engl J Med,2012

4. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations;Flaherty;N Engl J Med,2012

5. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma;Long;N Engl J Med,2014

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success;Current Oncology Reports;2024-06-08

2. Case 2-2024: A 57-Year-Old Woman with Melanoma and Fever;New England Journal of Medicine;2024-01-18

3. Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS;Melanoma Research;2023-11-13

4. Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer;Thyroid®;2023-11-01

5. Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients;Cancer Chemotherapy and Pharmacology;2023-03-22